Developer docs
API playgroundTry for free, no card

Search company profiles

Orano Med

Full company profile

uuid0003jx3

Namestring
Orano Med
Legal namestring
Orano Med
Websiteurl
oranomed.com
Company typeenum
Private
Founded yearint
2009
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersVillejuif, France
HQ citystring
Villejuif
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices6 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
targeted alpha therapy, radiopharmaceutical development, lead-212 radioisotope, oncology drug development, nuclear medicine manufacturing
Industry4 codes
PRIMARYHLAIAGAB
Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIAGAF
Radiopharmaceutical CDMO & Manufacturing (GMP Fill-Finish)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIAGAC
Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYEUAKAIAC
Radiopharmaceutical Manufacturing & CDMO (Synthesis, GMP, Packaging, QA/QC)
Energy, Utilities & Environment/Nuclear Energy/Nuclear Materials, Radiation Services & Isotopes (Medical/Industrial)
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Targeted Alpha Therapy Radiopharmaceuticals
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Licensing and Co-development Agreements
TypeLicensing Royalties
Description

Orano Med generates revenue through licensing deals and co-development partnerships with pharmaceutical companies. Sanofi paid approximately €300 million for a minority stake and licensed AlphaMedix for global commercialization. The company co-develops programs with Roche and Molecular Partners under royalty arrangements.

packagingdigest.com
2Lead-212 Isotope Supply
TypeManaged Services
Description

Orano Med supplies lead-212 isotopes and radiopharmaceutical manufacturing services to clinical trial partners. The company manufactures 212Pb-chelated products for its own trials and partner trials (Roche Phase 1, Molecular Partners trials) using its industrial platform in France and the United States.

oranomed.com
3Future Product Revenue (Pre-commercial)
TypeOne Time License
Description

Once AlphaMedix and other pipeline candidates receive regulatory approval, Orano Med will participate in commercial revenue through its partnership structure with Sanofi holding commercialization rights for AlphaMedix. Revenue will flow from radiopharmaceutical product sales to healthcare providers.

oranomed.com
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Infrastructure, Operations, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1AlphaMedix
Description

Lead-212 based radioligand therapy for neuroendocrine tumors, the company's most advanced clinical candidate.

oranomed.com
+4 more records
Core offering1 text field

Orano Med develops and manufactures targeted alpha therapy (TAT) radiopharmaceuticals based on the lead-212 (212Pb) radioisotope for treating rare and difficult-to-treat cancers. The company controls the entire production chain — from extracting lead-212 chemically from thorium-232 raw material, through chelation with targeting molecules (peptides, antibodies, DARPins), to GMP manufacturing of finished drug product. Its lead asset AlphaMedix is licensed to Sanofi for global commercialization, and additional pipeline programs are co-developed with Roche and Molecular Partners.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Phase 2 AlphaMedix achieved 60% objective response rate (ORR) in RLT-naïve GEP-NET patients and 34.6% ORR in RLT-exposed patients, with primary endpoints met in both local and blinded independent central review.
+3 more records
Product overview1 text field

Orano Med is a clinical-stage biotechnology company developing a new generation of targeted cancer therapies using lead-212 (212Pb) alpha-emitting radioisotope, known as targeted alpha therapy (alphathérapie ciblée). The company operates as a subsidiary of French nuclear group Orano and maintains a diversified pipeline of 212Pb-based radiopharmaceuticals targeting various cancer types. The core product AlphaMedix (212Pb-DOTAMTATE) targets neuroendocrine tumors and is licensed to Sanofi. Additional pipeline programs include 212Pb-GRPR for solid tumors (Phase 1), 212Pb-CEA-PRIT for colorectal cancer (with Roche), 212Pb-DARPin-DLL3 (MP0712) for small cell lung cancer (with Molecular Partners), 212Pb-PSMA for prostate cancer (Pre-IND), and 212Pb-DARPin-MSLN for ovarian cancer (PoC). Orano Med controls the entire supply chain from thorium-232 to finished radiopharmaceutical, operating industrial facilities in France (Laboratoire Maurice Tubiana, ATEF, ATLab Valenciennes) and the US (DDPU Plano, ATLab Indianapolis).

Product and service6 records
1AlphaMedix (212Pb-DOTAMTATE)
CategoryTargeted Alpha Therapy / Radiopharmaceutical
Description

Targeted alpha therapy using lead-212 conjugated to a somatostatin receptor-binding peptide (DOTAMTATE) for treating gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Achieved Phase 2 success with 60% ORR in RLT-naïve patients and 34.6% ORR in RLT-exposed patients. Received FDA Breakthrough Therapy Designation in February 2024. Licensed to Sanofi for global commercialization.

2212Pb-GRPR
CategoryTargeted Alpha Therapy / Radiopharmaceutical
Description

Gastrin-releasing peptide receptor (GRPR)-targeting peptide labeled with lead-212 for treating multiple solid tumor types including metastatic castration-resistant prostate cancer, HR+/HER2- breast cancer, colorectal cancer, cervical cancer, cutaneous melanoma, and non-small cell lung cancer. Currently in Phase 1 clinical trials in the United States.

3212Pb-CEA-PRIT
CategoryTargeted Alpha Therapy / Pretargeted Radioimmunotherapy
Description

Two-step pretargeted radioimmunotherapy using lead-212 to target carcinoembryonic antigen (CEA)-positive cancers including colorectal, pancreatic, gastric, and certain lung cancers. Developed in partnership with Roche using Roche's SPLIT antibody pretargeting technology. Advancing to Phase 1 clinical trial expected in H1 2026.

4212Pb-DARPin-DLL3 (MP0712)
CategoryTargeted Alpha Therapy / Radio-DARPin Radiopharmaceutical
Description

DLL3-targeting Radio-DARPin therapeutic candidate co-developed with Molecular Partners using lead-212 targeted alpha therapy for small cell lung cancer and other neuroendocrine cancers expressing DLL3. Phase 1/2a trial ongoing with initial clinical data expected in 2026.

5212Pb-PSMA
CategoryTargeted Alpha Therapy / Radiopharmaceutical
Description

Prostate-specific membrane antigen (PSMA)-targeting peptide labeled with lead-212 for prostate cancer treatment. Currently in Pre-IND stage of development.

6212Pb-DARPin-MSLN (MP0726)
CategoryTargeted Alpha Therapy / Radio-DARPin Radiopharmaceutical
Description

Mesothelin-targeting Radio-DARPin candidate co-developed with Molecular Partners for ovarian cancer and other MSLN-expressing cancers. Preclinical data presented at SNMMI 2025 showed promising tumor accumulation and selective binding in vivo.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-04
Description

Long-standing collaboration (since 2012) to develop two-step pretargeted radioimmunotherapy (PRIT) using lead-212 targeting carcinoembryonic antigen (CEA) in colorectal, pancreatic, gastric, and certain lung cancers. The partnership advanced from preclinical research to clinical development in Q3 2025. Roche sponsors the Phase 1 trial expected to start H1 2026. Orano Med manufactures and distributes chelated 212Pb from its French and US platforms. A shared R&D laboratory in Razès, France was built as part of the alliance.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-09-01
Description

Three-way collaboration with Orano Med and Sanofi for AlphaMedix (212Pb-DOTAMTATE). RadioMedix, a Houston-based clinical-stage radiopharmaceutical company, originally developed the AlphaMedix asset. The partnership combines RadioMedix's targeting molecule expertise, Orano Med's lead-212 production capabilities, and Sanofi's pharmaceutical commercialization power. AlphaMedix is in late-stage development for GEP-NETs.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-12
Description

Strategic collaboration to develop up to 10 targeted alpha radio-therapy programs using Molecular Partners' DARPin protein platform with Orano Med's lead-212. The most advanced candidate, MP0712 (DLL3-targeted Radio-DARPin for small cell lung cancer and neuroendocrine tumors), entered a Phase 1/2a trial in 2025. A second program targets mesothelin (MSLN). Molecular Partners leads development with royalty arrangements; Orano Med has option to co-develop two programs on a 50/50 basis with commercialization rights. Initial collaboration expanded by 6 new programs in 2025.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2011-01-01
Description

Subsidiary acquired in 2011, based in Plano, Texas alongside the DDPU. Macrocyclics provides advanced chelating technology for nuclear medicine, producing the chelants used in Orano Med's lead-212 therapies. Its expertise in chelation chemistry is critical to stable binding of lead-212 to targeting molecules. The company has been providing chelating technology since 1995.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Curium is a global nuclear medicine player producing diagnostic and therapeutic radiopharmaceuticals at commercial scale. Comparable as a vertically integrated radiopharma manufacturer/distributor with overlapping manufacturing and isotope capabilities.

TypeDirect peer
Description

Perspective Therapeutics is developing lead-212-based radiopharmaceuticals targeting PSMA and other antigens. The most direct head-to-head competitor on the same isotope, indicating platform validation but also near-term competitive overlap.

TypeBroad incumbent
Description

Novartis commercializes Pluvicto (177Lu-PSMA-617) and Lutathera (177Lu-DOTATATE), the leading radioligand therapies. Directly comparable as the dominant incumbent in targeted radiotherapy that Orano Med's lead-212 alpha therapies aim to disrupt or complement.

TypeDirect peer
Description

Fusion developed actinium-225-based targeted alpha therapies for cancer and was acquired by AstraZeneca. Highly comparable as a competing alpha-emitter radiopharma platform that exited via a major pharma acquisition, validating the M&A pathway for Orano Med.

TypeOthers
Description

Molecular Partners is Orano Med's development partner on the Radio-DARPin platform (up to 10 programs including MP0712). Comparable as the targeting-molecule engine that powers a subset of Orano Med's pipeline, with reciprocal alignment on program economics.

TypeDirect peer
Description

Lantheus is a commercial-stage radiopharmaceutical company with a portfolio spanning diagnostic and therapeutic agents (e.g., PNT2002/SOLAR-1 in PSMA). Comparable as a vertically integrated radiopharma player pursuing theranostic and targeted radioligand therapy.

TypeDirect peer
Description

Telix develops and commercializes radiopharmaceuticals including Illuccix (PSMA-PET imaging) and is advancing therapeutic programs. Comparable as a commercial-stage radiopharma competitor with overlapping theranostic ambitions and urological oncology focus.

TypeDirect peer
Description

ITM is a radiopharmaceutical company specializing in radionuclide supply (lutetium-177 and others) and targeted radiopharmaceutical development. Comparable as both a competing isotope supplier and a developer of targeted radioligand therapies.

TypeBroad incumbent
Description

Bayer developed and commercialized Xofigo (radium-223 dichloride), the first alpha-emitting radiopharmaceutical for cancer. Highly comparable as the historical alpha-therapy benchmark, with Bayer's former radiopharmaceutical head (now Orano Med's CMO) directly connecting the two.

TypeDirect peer
Description

POINT Biopharma developed PSMA-targeted radioligand therapy (PNT2002) and actinium-225 alpha therapy programs before Eli Lilly's acquisition. Comparable as a clinically staged radioligand therapy competitor that validates pharma appetite for the category.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles21 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Orano Med

Targeted Alpha Therapy Radiopharmaceuticalsoranomed.com

Orano Med firmographics

Firmographics
Name
Orano Med
Legal name
Orano Med
Website
https://oranomed.com
Company type
Private
Founded year
2009
Operating status
Operating
Headcount range
101–250 employees
Ownership category
akta.pro rank

Orano Med industry classification

Industry
Product category
Targeted Alpha Therapy Radiopharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAGAB
Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIAGAF
Radiopharmaceutical CDMO & Manufacturing (GMP Fill-Finish)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIAGAC
Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYEUAKAIAC
Radiopharmaceutical Manufacturing & CDMO (Synthesis, GMP, Packaging, QA/QC)
Energy, Utilities & Environment/Nuclear Energy/Nuclear Materials, Radiation Services & Isotopes (Medical/Industrial)

Keywords

  • Targeted alpha therapy
  • Radiopharmaceutical development
  • Lead-212 radioisotope
  • Oncology drug development
  • Nuclear medicine manufacturing

Where Orano Med is headquartered

Location

Headquarters

HQ city
Villejuif
HQ country
France
HQ region
Europe

Offices6 records

Markets served

Orano Med business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Infrastructure, Operations, Supply Chain, Marketing or Sales

Revenue model

  1. Licensing and Co-development Agreements: Orano Med generates revenue through licensing deals and co-development partnerships with pharmaceutical companies. Sanofi paid approximately €300 million for a minority stake and licensed AlphaMedix for global commercialization. The company co-develops programs with Roche and Molecular Partners under royalty arrangements.
  2. Lead-212 Isotope Supply: Orano Med supplies lead-212 isotopes and radiopharmaceutical manufacturing services to clinical trial partners. The company manufactures 212Pb-chelated products for its own trials and partner trials (Roche Phase 1, Molecular Partners trials) using its industrial platform in France and the United States.
  3. Future Product Revenue (Pre-commercial): Once AlphaMedix and other pipeline candidates receive regulatory approval, Orano Med will participate in commercial revenue through its partnership structure with Sanofi holding commercialization rights for AlphaMedix. Revenue will flow from radiopharmaceutical product sales to healthcare providers.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels9 records

Orano Med product offering

Product offering

Core offering

Orano Med develops and manufactures targeted alpha therapy (TAT) radiopharmaceuticals based on the lead-212 (212Pb) radioisotope for treating rare and difficult-to-treat cancers. The company controls the entire production chain — from extracting lead-212 chemically from thorium-232 raw material, through chelation with targeting molecules (peptides, antibodies, DARPins), to GMP manufacturing of finished drug product. Its lead asset AlphaMedix is licensed to Sanofi for global commercialization, and additional pipeline programs are co-developed with Roche and Molecular Partners.

Product overview

Orano Med is a clinical-stage biotechnology company developing a new generation of targeted cancer therapies using lead-212 (212Pb) alpha-emitting radioisotope, known as targeted alpha therapy (alphathérapie ciblée). The company operates as a subsidiary of French nuclear group Orano and maintains a diversified pipeline of 212Pb-based radiopharmaceuticals targeting various cancer types. The core product AlphaMedix (212Pb-DOTAMTATE) targets neuroendocrine tumors and is licensed to Sanofi. Additional pipeline programs include 212Pb-GRPR for solid tumors (Phase 1), 212Pb-CEA-PRIT for colorectal cancer (with Roche), 212Pb-DARPin-DLL3 (MP0712) for small cell lung cancer (with Molecular Partners), 212Pb-PSMA for prostate cancer (Pre-IND), and 212Pb-DARPin-MSLN for ovarian cancer (PoC). Orano Med controls the entire supply chain from thorium-232 to finished radiopharmaceutical, operating industrial facilities in France (Laboratoire Maurice Tubiana, ATEF, ATLab Valenciennes) and the US (DDPU Plano, ATLab Indianapolis).

Differentiator

Problem solved

Functional benefit

Brands

  • AlphaMedix: Lead-212 based radioligand therapy for neuroendocrine tumors, the company's most advanced clinical candidate.
  • Laboratoire Maurice Tubiana (LMT)
  • Advanced Thorium Extraction Facility (ATEF)
  • Drug Development & Preclinical Unit (DDPU)
  • Alpha Therapy Laboratory (ATLab)

Products and services

  • AlphaMedix (212Pb-DOTAMTATE) Targeted alpha therapy using lead-212 conjugated to a somatostatin receptor-binding peptide (DOTAMTATE) for treating gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Achieved Phase 2 success with 60% ORR in RLT-naïve patients and 34.6% ORR in RLT-exposed patients. Received FDA Breakthrough Therapy Designation in February 2024. Licensed to Sanofi for global commercialization.
  • 212Pb-GRPR Gastrin-releasing peptide receptor (GRPR)-targeting peptide labeled with lead-212 for treating multiple solid tumor types including metastatic castration-resistant prostate cancer, HR+/HER2- breast cancer, colorectal cancer, cervical cancer, cutaneous melanoma, and non-small cell lung cancer. Currently in Phase 1 clinical trials in the United States.
  • 212Pb-CEA-PRIT Two-step pretargeted radioimmunotherapy using lead-212 to target carcinoembryonic antigen (CEA)-positive cancers including colorectal, pancreatic, gastric, and certain lung cancers. Developed in partnership with Roche using Roche's SPLIT antibody pretargeting technology. Advancing to Phase 1 clinical trial expected in H1 2026.
  • 212Pb-DARPin-DLL3 (MP0712) DLL3-targeting Radio-DARPin therapeutic candidate co-developed with Molecular Partners using lead-212 targeted alpha therapy for small cell lung cancer and other neuroendocrine cancers expressing DLL3. Phase 1/2a trial ongoing with initial clinical data expected in 2026.
  • 212Pb-PSMA Prostate-specific membrane antigen (PSMA)-targeting peptide labeled with lead-212 for prostate cancer treatment. Currently in Pre-IND stage of development.
  • 212Pb-DARPin-MSLN (MP0726) Mesothelin-targeting Radio-DARPin candidate co-developed with Molecular Partners for ovarian cancer and other MSLN-expressing cancers. Preclinical data presented at SNMMI 2025 showed promising tumor accumulation and selective binding in vivo.

Quantifiable outcome

  • Phase 2 AlphaMedix achieved 60% objective response rate (ORR) in RLT-naïve GEP-NET patients and 34.6% ORR in RLT-exposed patients, with primary endpoints met in both local and blinded independent central review.
  • +3 more outcomes

Companies that use Orano Med

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Orano Med technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Orano Med partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • RochecoreStrategic or Co-development Partner · 4 December 2025Long-standing collaboration (since 2012) to develop two-step pretargeted radioimmunotherapy (PRIT) using lead-212 targeting carcinoembryonic antigen (CEA) in colorectal, pancreatic, gastric, and certain lung cancers. The partnership advanced from preclinical research to clinical development in Q3 2025. Roche sponsors the Phase 1 trial expected to start H1 2026. Orano Med manufactures and distributes chelated 212Pb from its French and US platforms. A shared R&D laboratory in Razès, France was built as part of the alliance.
  • RadioMedixcoreStrategic or Co-development Partner · 1 September 2024Three-way collaboration with Orano Med and Sanofi for AlphaMedix (212Pb-DOTAMTATE). RadioMedix, a Houston-based clinical-stage radiopharmaceutical company, originally developed the AlphaMedix asset. The partnership combines RadioMedix's targeting molecule expertise, Orano Med's lead-212 production capabilities, and Sanofi's pharmaceutical commercialization power. AlphaMedix is in late-stage development for GEP-NETs.
  • Molecular PartnerscoreStrategic or Co-development Partner · 12 January 2024Strategic collaboration to develop up to 10 targeted alpha radio-therapy programs using Molecular Partners' DARPin protein platform with Orano Med's lead-212. The most advanced candidate, MP0712 (DLL3-targeted Radio-DARPin for small cell lung cancer and neuroendocrine tumors), entered a Phase 1/2a trial in 2025. A second program targets mesothelin (MSLN). Molecular Partners leads development with royalty arrangements; Orano Med has option to co-develop two programs on a 50/50 basis with commercialization rights. Initial collaboration expanded by 6 new programs in 2025.
  • MacrocyclicscoreTechnology or Integration · 1 January 2011Subsidiary acquired in 2011, based in Plano, Texas alongside the DDPU. Macrocyclics provides advanced chelating technology for nuclear medicine, producing the chelants used in Orano Med's lead-212 therapies. Its expertise in chelation chemistry is critical to stable binding of lead-212 to targeting molecules. The company has been providing chelating technology since 1995.

Scale indicators9 records

Recent moves7 records

Expansion highlights5 records

Orano Med competitors and assessment

Company assessment

Broad incumbents

  • Curium: Curium is a global nuclear medicine player producing diagnostic and therapeutic radiopharmaceuticals at commercial scale. Comparable as a vertically integrated radiopharma manufacturer/distributor with overlapping manufacturing and isotope capabilities.
  • Novartis: Novartis commercializes Pluvicto (177Lu-PSMA-617) and Lutathera (177Lu-DOTATATE), the leading radioligand therapies. Directly comparable as the dominant incumbent in targeted radiotherapy that Orano Med's lead-212 alpha therapies aim to disrupt or complement.
  • Bayer: Bayer developed and commercialized Xofigo (radium-223 dichloride), the first alpha-emitting radiopharmaceutical for cancer. Highly comparable as the historical alpha-therapy benchmark, with Bayer's former radiopharmaceutical head (now Orano Med's CMO) directly connecting the two.

Direct peers

  • Perspective Therapeutics: Perspective Therapeutics is developing lead-212-based radiopharmaceuticals targeting PSMA and other antigens. The most direct head-to-head competitor on the same isotope, indicating platform validation but also near-term competitive overlap.
  • Fusion Pharmaceuticals (acquired by AstraZeneca): Fusion developed actinium-225-based targeted alpha therapies for cancer and was acquired by AstraZeneca. Highly comparable as a competing alpha-emitter radiopharma platform that exited via a major pharma acquisition, validating the M&A pathway for Orano Med.
  • Lantheus Holdings: Lantheus is a commercial-stage radiopharmaceutical company with a portfolio spanning diagnostic and therapeutic agents (e.g., PNT2002/SOLAR-1 in PSMA). Comparable as a vertically integrated radiopharma player pursuing theranostic and targeted radioligand therapy.
  • Telix Pharmaceuticals: Telix develops and commercializes radiopharmaceuticals including Illuccix (PSMA-PET imaging) and is advancing therapeutic programs. Comparable as a commercial-stage radiopharma competitor with overlapping theranostic ambitions and urological oncology focus.
  • ITM Isotope Technologies Munich: ITM is a radiopharmaceutical company specializing in radionuclide supply (lutetium-177 and others) and targeted radiopharmaceutical development. Comparable as both a competing isotope supplier and a developer of targeted radioligand therapies.
  • Point Biopharma (acquired by Eli Lilly): POINT Biopharma developed PSMA-targeted radioligand therapy (PNT2002) and actinium-225 alpha therapy programs before Eli Lilly's acquisition. Comparable as a clinically staged radioligand therapy competitor that validates pharma appetite for the category.

Others

  • Molecular Partners: Molecular Partners is Orano Med's development partner on the Radio-DARPin platform (up to 10 programs including MP0712). Comparable as the targeting-molecule engine that powers a subset of Orano Med's pipeline, with reciprocal alignment on program economics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Orano Med social profiles

Digital presence

Orano Med financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Orano Med leadership team

Management profile

Number of profiles

Profiles21 records

Orano Med subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Orano Med funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Orano Med M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Orano Med

What does Orano Med do?

Orano Med develops and manufactures targeted alpha therapy (TAT) radiopharmaceuticals based on the lead-212 (212Pb) radioisotope for treating rare and difficult-to-treat cancers. The company controls the entire production chain — from extracting lead-212 chemically from thorium-232 raw material, through chelation with targeting molecules (peptides, antibodies, DARPins), to GMP manufacturing of finished drug product. Its lead asset AlphaMedix is licensed to Sanofi for global commercialization, and additional pipeline programs are co-developed with Roche and Molecular Partners.

Is Orano Med a public or private company?

Orano Med is a private company. It is classified as corporate owned and is currently operating.

When was Orano Med founded?

Orano Med was founded in 2009. It employs 101 to 250 people.

Where is Orano Med based?

Orano Med is headquartered in Villejuif, France, in the Europe region.

How does Orano Med make money?

Three revenue lines are on record. Licensing and Co-development Agreements are the primary driver. The others are lead-212 Isotope Supply and future Product Revenue (Pre-commercial).

Who are Orano Med's main competitors?

Broad incumbents on record are Curium, Novartis and Bayer. Direct peers are Perspective Therapeutics, Fusion Pharmaceuticals (acquired by AstraZeneca), Lantheus Holdings, Telix Pharmaceuticals, ITM Isotope Technologies Munich and Point Biopharma (acquired by Eli Lilly). Molecular Partners is listed as an others.

Does Orano Med have an API?

No public API is recorded for Orano Med.

What industry is Orano Med in?

Orano Med's product category is Targeted Alpha Therapy Radiopharmaceuticals. Its primary akta.pro industry code is HLAIAGAB, Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy), with a secondary code of HLAIAGAF, Radiopharmaceutical CDMO & Manufacturing (GMP Fill-Finish). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PrwebThe Healthcare Technology Report Announces The Top Biotech and Life Sciences Companies of 2026The Healthcare Technology Report announced its 2026 Top Biotech and Life Sciences Companies, including Celcuity, Summit Therapeutics, Novavax, and Orano Med. Highlights include Celcuity's FDA approval for REVTORPYK, Summit's Phase 3 lung cancer data and $2 billion AstraZeneca investment, and Novavax's Pfizer licensing deal.Business & FinancialNeuroendocrine Tumors Clinical Trials Update 2026: Phase-Wise Pipeline Status, Drug Profiles, And Key Developers Camurus, Orano Med, Vyriad, Pfizer, Takeda Oncology, Hutchison Medipharma, ProvectusDelveInsight's 2026 Neuroendocrine Tumors pipeline report profiles therapies from Camurus, Orano Med, and others. The FDA approved BRAVNETSA and BEXLUTRY in September 2026, and ITM's Phase III COMPETE trial showed ITM-11 improved progression-free survival versus everolimus.FinancialContent Business PageOrano Med Appoints Matthew Fyfe as Chief Scientific OfficerOrano Med appointed Matthew Fyfe as Chief Scientific Officer, bringing over 25 years of drug discovery experience. He will lead R&D, focusing on lead-212-based targeted alpha therapies, and previously served as CSO at Outrun Therapeutics.FinancialContent Business PageOrano Med Inaugurates ATLab Valenciennes, Europe’s First Industrial Facility Dedicated to the Production of Lead-212-Based Targeted Alpha TherapiesOrano Med inaugurated ATLab Valenciennes, Europe's first industrial facility for lead-212-based targeted alpha therapies, in Onnaing, France. The €29 million, 3,000 m² site will produce up to 10,000 doses annually, with potential to multiply by five, and creates about 25 jobs.MorningstarOrano Med Inaugurates ATLab Valenciennes, Europe’s First Industrial Facility Dedicated to the Production of Lead-212-Based Targeted Alpha TherapiesOrano Med inaugurated ATLab Valenciennes, Europe's first industrial facility for lead-212-based targeted alpha therapies, in Onnaing, France. The €29 million, 3,000 m² site can produce up to 10,000 doses annually, with potential to multiply by five, and will create about 25 jobs.Business Wire BlogOrano Med Inaugurates ATLab Valenciennes, Europe’s First Industrial Facility Dedicated to the Production of Lead-212-Based Targeted Alpha TherapiesOrano Med inaugurated ATLab Valenciennes, Europe's first industrial facility for lead-212-based targeted alpha therapies. The €29 million, 3,000 m² site can produce up to 10,000 doses annually, with potential fivefold expansion, and will create about 25 jobs. The facility supports production within 24 hours due to lead-212's 10.6-hour half-life.FinancialContent Business PageOrano Med Provides Half-Year Progress Report and Business OutlookOrano Med, a clinical-stage biotechnology subsidiary of Orano Group developing lead-212-based targeted alpha therapies for cancer, released its H1 2026 progress report highlighting corporate, clinical and industrial advancements. The company expanded its clinical pipeline to four active lead-212 studies, inaugurated its new R&D center in Villejuif, France, and secured a EUR 125 million credit line from the European Investment Bank to fund industrial infrastructure including the ATEF facility in Bessines-sur-Gartempe. Key clinical programs include AlphaMedix (with Sanofi and RadioMedix), a GRPR-targeting therapy, a DLL3 program (with Molecular Partners), and a CEA program (with Roche), with multiple trials advancing toward regulatory milestones.BioSpaceOrano Med Provides Half-Year Progress Report and Business OutlookOrano Med reported first-half 2026 progress, including four active lead-212 clinical trials and a EUR 125 million EIB loan. The company inaugurated its French R&D center and is ramping up thorium-228 production. It plans to start the next AlphaMedix trial by end of 2026.Business Wire BlogOrano Med Provides Half-Year Progress Report and Business OutlookOrano Med, a clinical-stage biotech subsidiary of Orano Group specializing in nuclear medicine, provided a half-year progress update for 2026, reporting significant advancements across its lead-212 targeted alpha therapy pipeline. The company inaugurated a new R&D center in Villejuif, France, expanded its clinical portfolio to four active lead-212 trials, and secured a EUR 125 million credit line from the European Investment Bank to fund industrial infrastructure including the world's first large-scale thorium-228 production facility. Key clinical programs including AlphaMedix (with Sanofi and RadioMedix), GRPR-targeting therapy, and partnerships with Molecular Partners and Roche are advancing toward clinical milestones, with new study protocols targeting regulatory submissions in late 2026.